(Q73182990)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

M A Dooley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Hogan

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

C Jennette

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R Falk

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 April 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1188-1195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9083285%20AND%20SRC:MED&resulttype=core&format=json

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Intermittent intravenous cyclophosphamide therapy for lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Epidemiologic studies on systemic lupus erythematosus comparative data for new york city and jefferson county, alabama, 1956–1965

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Survivorship in systemic lupus erythematosus: relationship to race and pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Lupus nephritis. Clinical course as related to morphologic forms and their transitions

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Prognostic determinants in lupus nephritis: a long-term clinicopathologic study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The treatment of lupus nephritis by methyl prednisolone pulse therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Prognostic factors in lupus nephritis. Contribution of renal histologic data

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The prognosis of lupus nephritis. Role of clinical-pathologic correlations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Renal histology and clinical course of systemic lupus erythematosus. A prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Clinical features of systemic lupus erythematosus: differences related to race and age of onset

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Morbidity of systemic lupus erythematosus: role of race and socioeconomic status

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The prognosis of lupus nephritis in African-Americans: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Nervous system involvement in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Relationship between C4 null genes, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021

Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.162

7 January 2021